IL6 and cancer: Surprisingly, blocking IL-6 trans-signaling with sgp130Fc has therapeutic effects on reducing tumor progression in murine cancer models, including murine colitis-associated cancer (CAC)65,66, lung adenocarcinoma10, and hepatocellular carcinoma (HCC) models105,106.